Key Points
- Director Christy Jones sold 6,430 Beta Bionics shares for approximately $147,890, reducing her holdings by 24.7% to 19,564 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Beta Bionics plans to integrate its iLet Bionic Pancreas and Mobi systems with Senseonics’ Eversense 365 continuous glucose monitor, with the combined system expected to launch commercially in the fourth quarter of 2026.
- The company faces securities litigation alleging it failed to disclose FDA concerns and more than 18,000 iLet complaints, while analysts remain generally bullish with a “Moderate Buy” consensus rating and a $22.45 average price target.
Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) Director Christy Jones sold 6,430 shares of the company's stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total transaction of $147,890.00. Following the completion of the transaction, the director owned 19,564 shares of the company's stock, valued at $449,972. This trade represents a 24.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Beta Bionics Price Performance
Beta Bionics stock opened at $22.19 on Thursday. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71. The company has a market capitalization of $998.33 million, a price-to-earnings ratio of -13.45 and a beta of 3.37. The firm's fifty day moving average price is $17.98 and its 200 day moving average price is $14.29.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The company had revenue of $32.01 million during the quarter. Analysts forecast that Beta Bionics, Inc. will post -2.06 earnings per share for the current fiscal year.
Key Headlines Impacting Beta Bionics
Here are the key news stories impacting Beta Bionics this week:
- Positive Sentiment: Beta Bionics announced a partnership with Senseonics to integrate its iLet Bionic Pancreas and mint automated insulin-delivery systems with Senseonics’ Eversense 365 continuous glucose monitor. The combined iLet-Eversense system is expected to launch commercially in the fourth quarter of 2026, potentially expanding customer choice and strengthening BBNX’s competitive position in automated diabetes management. Beta Bionics Announces Agreement to Integrate Its Systems with Senseonics’ Eversense 365
- Neutral Sentiment: Multiple law firms publicized the same pending securities class action against Beta Bionics. The proposed class covers investors who purchased shares from July 30, 2025, through February 24, 2026, with November 3, 2026, set as the lead-plaintiff deadline. The notices themselves largely repeat existing litigation information, but they increase visibility around the claims and potential legal costs. BBNX Investor Deadline and Class Action Notice
- Negative Sentiment: The lawsuit alleges Beta Bionics failed to disclose or adequately describe FDA concerns, including a June 2025 Form 483 and more than 18,000 iLet complaints. The allegations claim subsequent disclosures about the FDA’s concerns and medical-device safety led to a sharp decline in BBNX shares. These claims have not been proven, but the litigation creates regulatory, reputational and financial uncertainty. Johnson Fistel BBNX Investor Alert
- Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her holdings by about 24.7%. The transaction was made under a pre-arranged Rule 10b5-1 trading plan, which somewhat limits its value as a discretionary bearish signal; however, it adds to reported insider-selling activity and there have been no recent open-market insider purchases highlighted in the coverage. SEC Form 4 Filing
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of BBNX. Eventide Asset Management LLC boosted its holdings in shares of Beta Bionics by 0.8% in the 4th quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company's stock valued at $152,233,000 after buying an additional 37,476 shares during the period. BlackRock Inc. acquired a new stake in Beta Bionics during the second quarter worth about $52,340,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Beta Bionics in the fourth quarter worth about $40,437,000. Eversept Partners LP bought a new position in Beta Bionics in the fourth quarter worth about $20,667,000. Finally, 12 West Capital Management LP acquired a new position in Beta Bionics in the fourth quarter valued at approximately $17,520,000.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the company. Leerink Partners increased their target price on Beta Bionics from $24.00 to $27.00 and gave the company an "outperform" rating in a research note on Monday, September 14th. Weiss Ratings upgraded shares of Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 18th. Wells Fargo & Company started coverage on shares of Beta Bionics in a research report on Wednesday. They issued an "overweight" rating and a $28.00 target price for the company. The Goldman Sachs Group upped their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Finally, Wall Street Zen raised shares of Beta Bionics from a "sell" rating to a "hold" rating in a research report on Saturday, September 19th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $22.45.
Read Our Latest Report on BBNX
About Beta Bionics
(
Get Free Report)
Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.
The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
